TABLE 2

Outcomes for All Subjects and for Each Treatment Group

OutcomeDuration for All Subjects (N = 242)Treatment Group
Ipratropium Only (n = 94)Magnesium Only (n = 13)Magnesium and Ipratropium (n = 42)No Adjunct (n = 93)
Duration of continuous albuterol, h, median (IQR)7.0 (2.8–12.0)4.9 (2.0–10.0)a7.5 (2.5–16.0)11.0 (5.6–28.6)b7.0 (3.5–10.4)a
Time to q4 albuterol, h, mean (IQR)38.7 (24.9–64.6)44.3 (29.5–64.6)a,b50.7 (28.8–67.3)b71.3 (46.9–99.3)b26.7 (19.7–38.3)a
Hospital LOS, h, mean (IQR)49.0 (32.0–77.7)57.7 (41.1–79.1)a,b57.0 (42.3–83.8)b77.3 (50.8–104.4)b33.7 (26.8–45.2)a
  • a P < .05 versus dual therapy (magnesium and ipratropium) by Kruskal-Wallis ANOVA with Dunn’s test.

  • b P < .05 versus no adjunctive therapy by Kruskal-Wallis ANOVA with Dunn’s test.